CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.） セレクタ・バイオサイエンシ―ズCLRBのチャート
CLRBの企業情報
| symbol | CLRB |
|---|---|
| 会社名 | Cellectar Biosciences Inc （セレクタ・バイオサイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates. セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。 |
| 本社所在地 | 3301 Agriculture Drive Madison WI 53716 USA |
| 代表者氏名 | Stephen Anthony Hill スティーブン・アンソニー・ヒル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 608-441-8120 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cellectar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.53883 |
| 終値（lastsale） | 2.715 |
| 時価総額（marketcap） | 10311094.875 |
| 時価総額 | 時価総額（百万ドル） 10.21615 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.03918 |
| 当期純利益 | 当期純利益（百万ドル） -15.39489 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75. |
CLRBのテクニカル分析
CLRBのニュース
Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics 2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed 2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20 2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20 2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter 2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all
Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics 2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed 2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20 2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20 2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter 2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed 2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20 2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20 2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter 2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic 2020/06/04 12:13:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 3) Cellectar Biosciences Inc (NASDAQ: CLRB ) (priced a $20-million common stock offering) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Genfit SA (NASDAQ: GNFT ) Stocks In Focus Kezar Reports Positive Early Stage Results For KZR-616 In Systemic Lupus Erythematosus Kezar Life Sciences, Inc. (NASDAQ: KZR ) announced updated results from the Phase 1b portion of the Phase 1b/2 MISSION study, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis, showing overall improvements across seven measures of disease activity.